Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: Phase i clinical study

Gene Therapy

Volumn 20, Issue 7, 2013, Pages 717-722

  Kim, J S ^a   Hwang, H Y ^b   Cho, K R ^c   Park, E A ^b   Lee, W ^b   Paeng, J C ^b   Lee, D S ^b   Kim, H K ^b   Sohn, D W ^b   Kim, K B ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Cheju Halla General Hospital   (South Korea)

Author keywords

Angiogenesis; Gene transfer; Hepatocyte growth factor; Incomplete revascularization; Naked DNA

Indexed keywords

ISOPROTEIN; SCATTER FACTOR; UNCLASSIFIED DRUG; VM202 PROTEIN;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; DIASTOLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFUSION; HEART TRANSPLANTATION; HUMAN; ISCHEMIC HEART DISEASE; LEFT CORONARY ARTERY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REST; RIGHT CORONARY ARTERY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLE;

AGED; CORONARY ARTERY BYPASS; FEMALE; GENE TRANSFER TECHNIQUES; HEART; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VACCINES, DNA;

EID: 84880235380     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.87     Document Type: Article

References (27)

1. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis-how many patients might be eligible? Am J Cardiol 1999; 84: 598-600A8.
2. Scott R, Blackstone EH, McCarthy PM, Lytle BW, Loop FD, White JA et al. Isolated bypass grafting of the left internal thoracic artery to the left anterior descending coronary artery: late consequences of incomplete revascularization. J Thorac Cardiovasc Surg 2000; 120: 173-184.
3. Caputo M, Reeves BC, Rajkaruna C, Awair H, Angelini GD. Incomplete revascularization during OPCAB surgery is associated with reduced mid-term event-free survival. Ann Thorac Surg 2005; 80: 2141-2147.
4. Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991; 6: 501-504.
5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
6. Morishita R, Aoki M, Hashiya N, Yamasaki K, Kurinami H, Shimizu S et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004; 4: 199-206.
7. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chatterjee S, Berry MF et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003; 108(Suppl 1): II230-II236.
8. Funatsu T, Sawa Y, Ohtake S, Takahashi T, Matsumiya G, Matsuura N et al. Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor. J Thorac Cardiovasc Surg 2002; 124: 1099-1105.
9. Ahmet I, Sawa Y, Yamaguchi T, Matsuda H. Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 2003; 75: 1283-1287.
10. Yasuda S, Goto Y, Baba T, Satoh T, Sumida H, Miyazaki S et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 2000; 36: 115-121.
11. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552-2558.
12. Jin H, Yang R, Li W, Ogasawara AK, Schwall R, Eberhard DA et al. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. J Pharmacol Exp Ther 2003; 304: 654-660.
13. Cho KR, Choi JS, Hahn W, Kim DS, Park JS, Lee DS et al. Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg 2008; 34: 857-863.
14. Henry TD, Hirsch AT, Goldman J, Wang YL, Lips DL, McMillan WD et al. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Therapy 2011; 18: 788-794.
15. Gu Y, Zhang J, Guo L, Cui S, Li X, Ding D et al. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia. J Gene Med 2011; 13: 602-610.
16. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203-209.
17. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58-65.
18. Carlsson M, Osman NF, Ursell PC, Martin AJ, Saeed M. Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium. American journal of physiology. Heart Circ Physiol 2008; 295: H522-H532.
19. Saeed M, Saloner D, Do L, Wilson M, Martin A. Cardiovascular magnetic resonance imaging in delivering and evaluating the efficacy of hepatocyte growth factor gene in chronic infarct scar. Cardiovasc Revasc Med 2011; 12: 111-122.
20. Perin EC, Silva GV, Vela DC, Zheng Y, Baimbridge F, Gahremanpour A et al. Human hepatocyte growth factor (VM202) gene therapy via transendocardial injection in a pig model of chronic myocardial ischemia. J Card Fail 2011; 17: 601-611.
21. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. ProcJapan Acad 2010; 86(6): 588-610.
22. Burr AW, Toole K, Chapman C, Hines JE, Burt AD. Anti-hepatocyte growth factor antibody inhibits hepatocyte proliferation during liver regeneration. J Pathol 1998; 185: 298-302.
23. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM. Simoons ML. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003; 107: 524-530.
24. Pyun WB, Hahn W, Kim DS, Yoo WS, Lee SD, Won JH et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Therapy 2010; 17: 1442-1452.
25. Hahn W, Pyun WB, Kim DS, Yoo WS, Lee SD, Won JH et al. Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model. J Gene Med 2011; 13: 549-555.
26. Lee Y, Park EJ, Yu SS, Kim DK, Kim S. Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun 2000; 272: 230-235.
27. Kim KB, Cho KR, Chang WI, Lim C, Ham BM, Kim YL. Bilateral skeletonized internal thoracic artery graftings in off-pump coronary artery bypass: early result of Y versus in situ grafts. Ann Thorac Surg 2002; 74: S1371-S1376.